Chromocell Therapeutics (CHRO) Competitors $1.34 +0.08 (+6.35%) Closing price 07/1/2025Extended Trading$1.34 0.00 (0.00%) As of 07/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock CHRO vs. MRSN, CLNN, LTRN, KZR, OKUR, RNTX, ESLA, BDRX, KALA, and EGRXShould you be buying Chromocell Therapeutics stock or one of its competitors? The main competitors of Chromocell Therapeutics include Mersana Therapeutics (MRSN), Clene (CLNN), Lantern Pharma (LTRN), Kezar Life Sciences (KZR), OnKure Therapeutics (OKUR), Rein Therapeutics (RNTX), Estrella Immunopharma (ESLA), Biodexa Pharmaceuticals (BDRX), KALA BIO (KALA), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical products" industry. Chromocell Therapeutics vs. Its Competitors Mersana Therapeutics Clene Lantern Pharma Kezar Life Sciences OnKure Therapeutics Rein Therapeutics Estrella Immunopharma Biodexa Pharmaceuticals KALA BIO Eagle Pharmaceuticals Mersana Therapeutics (NASDAQ:MRSN) and Chromocell Therapeutics (NYSE:CHRO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment. Which has stronger valuation & earnings, MRSN or CHRO? Chromocell Therapeutics has lower revenue, but higher earnings than Mersana Therapeutics. Chromocell Therapeutics is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMersana Therapeutics$40.50M1.01-$69.19M-$0.59-0.55Chromocell TherapeuticsN/AN/A-$7.38M-$1.24-1.08 Which has more volatility and risk, MRSN or CHRO? Mersana Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Chromocell Therapeutics has a beta of 3.63, suggesting that its stock price is 263% more volatile than the S&P 500. Do analysts prefer MRSN or CHRO? Mersana Therapeutics currently has a consensus target price of $5.20, suggesting a potential upside of 1,490.21%. Given Mersana Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Mersana Therapeutics is more favorable than Chromocell Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mersana Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Chromocell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is MRSN or CHRO more profitable? Chromocell Therapeutics has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -217.63%. Chromocell Therapeutics' return on equity of 0.00% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mersana Therapeutics-217.63% -990.16% -48.87% Chromocell Therapeutics N/A N/A -453.90% Does the media prefer MRSN or CHRO? In the previous week, Mersana Therapeutics had 3 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 3 mentions for Mersana Therapeutics and 0 mentions for Chromocell Therapeutics. Chromocell Therapeutics' average media sentiment score of 0.00 beat Mersana Therapeutics' score of -0.42 indicating that Chromocell Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Mersana Therapeutics Neutral Chromocell Therapeutics Neutral Do insiders and institutionals hold more shares of MRSN or CHRO? 93.9% of Mersana Therapeutics shares are owned by institutional investors. Comparatively, 78.0% of Chromocell Therapeutics shares are owned by institutional investors. 13.0% of Mersana Therapeutics shares are owned by insiders. Comparatively, 16.4% of Chromocell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryMersana Therapeutics beats Chromocell Therapeutics on 10 of the 16 factors compared between the two stocks. Get Chromocell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CHRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRO vs. The Competition Export to ExcelMetricChromocell TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$8.69M$207.74M$5.46B$20.45BDividend YieldN/AN/A5.24%3.72%P/E Ratio-1.08N/A27.0127.80Price / SalesN/A259.79380.1449.81Price / CashN/A22.4426.2118.22Price / Book-0.815.707.994.58Net Income-$7.38M-$96.61M$3.16B$982.91M7 Day Performance-90.07%1.15%3.69%1.31%1 Month Performance-88.04%0.30%2.91%4.85%1 Year Performance-87.36%10.37%34.30%14.09% Chromocell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHROChromocell TherapeuticsN/A$1.34+6.3%N/A-89.1%$8.69MN/A-1.084Gap UpHigh Trading VolumeMRSNMersana Therapeutics3.6704 of 5 stars$0.28-5.1%$5.20+1,750.5%-83.4%$35.02M$40.50M-0.48150CLNNClene2.6626 of 5 stars$3.87-1.0%$40.00+933.1%-44.5%$34.93M$340K-0.96100LTRNLantern Pharma2.4493 of 5 stars$3.14-0.8%$25.00+697.4%-28.1%$33.80MN/A-1.7020Positive NewsGap UpKZRKezar Life Sciences4.0422 of 5 stars$4.43-3.4%$39.50+792.7%-21.6%$32.33MN/A-0.4160Negative NewsOKUROnKure Therapeutics3.1247 of 5 stars$2.39flat$32.33+1,252.9%N/A$32.29MN/A-0.45N/ARNTXRein TherapeuticsN/A$1.45+3.6%N/AN/A$32.12MN/A-0.519ESLAEstrella Immunopharma2.1967 of 5 stars$0.88-8.9%$16.00+1,728.6%-27.1%$31.65MN/A-3.37N/APositive NewsGap DownBDRXBiodexa PharmaceuticalsN/A$0.86-1.2%N/AN/A$31.24M$470K0.0020Upcoming EarningsKALAKALA BIO3.4724 of 5 stars$4.78+0.5%$13.50+182.2%-23.5%$31.10M$3.89M-0.5930High Trading VolumeEGRXEagle PharmaceuticalsN/A$2.36-18.6%N/A-45.5%$30.65M$257.55M0.00100 Related Companies and Tools Related Companies Mersana Therapeutics Competitors Clene Competitors Lantern Pharma Competitors Kezar Life Sciences Competitors OnKure Therapeutics Competitors Rein Therapeutics Competitors Estrella Immunopharma Competitors Biodexa Pharmaceuticals Competitors KALA BIO Competitors Eagle Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CHRO) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
